RxDoctor Payments Data

Indu Shivaram, MD

Internal Medicine · Morehead, KYNPI 1194817619

Payments from drug & device makers

$951in general payments, 2019–2025

Across 56 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$679
  • AstraZeneca$149
  • Medtronic$49
  • Sanofi$42
  • Boehringer Ingelheim$17
  • Gilead$14

What the payments were for

  • Food & beverage$93598%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK42$679
AstraZeneca9$149
Medtronic1$49
Sanofi2$42
Boehringer Ingelheim1$17
Gilead1$14

How this compares

$951 in reported general payments places this provider in the 60th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$66,215
Medicare patients
238
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter580$511,960
Spiriva RespimatTiotropium Bromide34$27,312
SymbicortBudesonide/Formoterol Fumarate32$8,166
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,925
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$5,613
DuleraMometasone/Formoterol16$5,201
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$4,522
Roflumilast72$4,086
Albuterol Sulfate HfaAlbuterol Sulfate140$3,512
Ventolin HfaAlbuterol Sulfate13$827
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate11$582
Montelukast Sodium49$427
Fluticasone Propionate46$321
Omeprazole34$300
Famotidine54$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$679$519,885596 claims
Boehringer IngelheimSpiriva Respimat$17$27,31234 claims
AstraZenecaSymbicort$149$8,16632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Morehead

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →